The cell line secretome, a suitable tool for investigating proteins released in vivo by tumors: Application to the study of p53-modulated proteins secreted in lung cancer cells

Journal of Proteome Research

Volumn 8, Issue 10, 2009, Pages 4579-4591

  Chenau, Jérôme ^a   Michelland, Sylvie ^a,b   De Fraipont, Florence ^a,b   Josserand, Véronique ^a   Coll, Jean Luc ^a   Favrot, Marie Christine ^a,b   Seve, Michel ^a,b  

^a UNIV GRENOBLE ALPES   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

iTRAQ; Lung cancer; p53; Proteomics; Secretome; Xenograft mouse model

Indexed keywords

CYTOKINE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 19; GROWTH DIFFERENTIATION FACTOR 15; PROTEIN P53; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL CLONE; CELL LINE; CONTROLLED STUDY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; FEMALE; GENE DELETION; HOMOZYGOSITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN SECRETION; PROTEIN STABILITY; SECRETOME; XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CHROMATOGRAPHY, LIQUID; FIBROBLAST GROWTH FACTORS; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; ISOTOPE LABELING; MICE; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; PROTEOME; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MUS;

EID: 70349972378     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr900383g     Document Type: Article

References (93)

1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M. J. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58 (2), 71-96.
2. Smith, R. A.; Glynn, T. J. Epidemiology of lung cancer. Radiol. Clin. North Am. 2000, 38 (3), 453-470
3. Gridelli, C.; Rossi, A.; Maione, P. Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents. Oncogene 2003, 22 (42), 6629-6638 (Pubitemid 37372343)
4. Hoffman, P. C.; Mauer, A. M.; Vokes, E. E. Lung cancer. Lancet 2000, 355 (9202), 479-485
5. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell 2000, 100 (1), 57-70.
6. Guimaraes, D. P.; Hainaut, P. TP53: a key gene in human cancer. Biochimie 2002, 84 (1), 83-93. (Pubitemid 34477096)
7. Robles, A. I.; Linke, S. P.; Harris, C. C. The p53 network in lung carcinogenesis. Oncogene 2002, 21 (45), 6898-6907
8. Szymanska, K.; Hainaut, P. TP53 and mutations in human cancer. Acta Biochim. Pol. 2003, 50 (1), 231-238
9. Levine, A. J.; Momand, J.; Finlay, C. A. The p53 tumour suppressor gene. Nature 1991, 351 (6326), 453-456
10. Lewis, P. D.; Parry, J. M. In silico p53 mutation hotspots in lung cancer. Carcinogenesis 2004, 25 (7), 1099-1107
11. Brambilla, E.; Negoescu, A.; Gazzeri, S.; Lantuejoul, S.; Moro, D.; Brambilla, C.; Coll, J. L. Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors. Am. J. Pathol. 1996, 149 (6), 1941-1952 (Pubitemid 26415213)
12. Donehower, L. A.; Harvey, M.; Slagle, B. L.; McArthur, M. J.; Montgomery, C. A., Jr.; Butel, J. S.; Bradley, A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992, 356 (6366), 215-221
13. Coll, J. L.; Negoescu, A.; Louis, N.; Sachs, L.; Tenaud, C.; Girardot, V.; Demeinex, B.; Brambilla, E.; Brambilla, C.; Favrot, M. Antitumor activity of bax and p53 naked gene transfer in lung cancer: in vitro and in vivo analysis. Hum. Gene Ther. 1998, 9 (14), 2063-2074 (Pubitemid 28463924)
14. Zigrino, P.; Loffek, S.; Mauch, C. Tumor-stroma interactions: their role in the control of tumor cell invasion. Biochimie 2005, 87 (3-4), 321-328 (Pubitemid 40387611)
15. Van Meir, E. G.; Roemer, K.; Diserens, A. C.; Kikuchi, T.; Rempel, S. A.; Haas, M.; Huang, H. J.; Friedmann, T.; de Tribolet, N.; Cavenee, W. K. Single cell monitoring of growth arrest and morphological changes induced by transfer of wild-type p53 alleles to glioblastoma cells. Proc. Natl. Acad. Sci. U.S.A. 1995, 92 (4), 1008-1012
16. Gu, S.; Liu, Z.; Pan, S.; Jiang, Z.; Lu, H.; Amit, O.; Bradbury, E. M.; Hu, C. A.; Chen, X. Global investigation of p53-induced apoptosis through quantitative proteomic profiling using comparative amino acid-coded tagging. Mol. Cell. Proteomics 2004, 3 (10), 998-1008. (Pubitemid 40361234)
17. Sun, Y. p53 and its downstream proteins as molecular targets of cancer. Mol. Carcinog. 2006, 45 (6), 409-415
18. Rahman-Roblick, R.; Roblick, U. J.; Hellman, U.; Conrotto, P.; Liu, T.; Becker, S.; Hirschberg, D.; Jornvall, H.; Auer, G.; Wiman, K. G. p53 targets identified by protein expression profiling. Proc. Natl. Acad. Sci. U.S.A. 2007, 104 (13), 5401-5406 (Pubitemid 47175692)
19. Khwaja, F. W.; Svoboda, P.; Reed, M.; Pohl, J.; Pyrzynska, B.; Van Meir, E. G. Proteomic identification of the wt-p53-regulated tumor cell secretome. Oncogene 2006, 25, 7650-7661 (Pubitemid 44924478)
20. Hathout, Y. Approaches to the study of the cell secretome. Expert Rev. Proteomics 2007, 4 (2), 239-248
21. Volmer, M. W.; Stuhler, K.; Zapatka, M.; Schoneck, A.; Klein-Scory, S.; Schmiegel, W.; Meyer, H. E.; Schwarte-Waldhoff, I. Differential proteome analysis of conditioned media to detect Smad4 regulated secreted biomarkers in colon cancer. Proteomics 2005, 5 (10), 2587-2601 (Pubitemid 40966486)
22. Xue, H.; Lu, B.; Lai, M. The cancer secretome: a reservoir of biomarkers. J. Transl. Med. 2008, 6, 52.
23. Gronborg, M.; Kristiansen, T. Z.; Iwahori, A.; Chang, R.; Reddy, R.; Sato, N.; Molina, H.; Jensen, O. N.; Hruban, R. H.; Goggins, M. G.; Maitra, A.; Pandey, A. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol. Cell. Proteomics 2006, 5 (1), 157-171 (Pubitemid 43169348)
24. Zhong, L.; Roybal, J.; Chaerkady, R.; Zhang, W.; Choi, K.; Alvarez, C. A.; Tran, H.; Creighton, C. J.; Yan, S.; Strieter, R. M.; Pandey, A.; Kurie, J. M. Identification of secreted proteins that mediate cellcell interactions in an in vitro model of the lung cancer microenvironment. Cancer Res. 2008, 68 (17), 7237-7245
25. Martin, D. B.; Gifford, D. R.; Wright, M. E.; Keller, A.; Yi, E.; Goodlett, D. R.; Aebersold, R.; Nelson, P. S. Quantitative proteomic analysis of proteins released by neoplastic prostate epithelium. Cancer Res. 2004, 64 (1), 347-355
26. Takahashi, T.; Carbone, D.; Takahashi, T.; Nau, M. M.; Hida, T.; Linnoila, I.; Ueda, R.; Minna, J. D. Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res. 1992, 52 (8), 2340-2343
27. Dubrez, L.; Coll, J. L.; Hurbin, A.; Solary, E.; Favrot, M. C. Caffeine sensitizes human H358 cell line to p53-mediated apoptosis by inducing mitochondrial translocation and conformational change of BAX protein. J. Biol. Chem. 2001, 276 (42), 38980-38987 (Pubitemid 37371264)
28. Dubrez, L.; Coll, J. L.; Hurbin, A.; de Fraipont, F.; Lantejoul, S.; Favrot, M. C. Cell cycle arrest is sufficient for p53-mediated tumor regression. Gene Ther. 2001, 8 (22), 1705-1712
29. Hurbin, A.; Dubrez, L.; Coll, J. L.; Favrot, M. C. Inhibition of apoptosis by amphiregulin via an insulin-like growth factor-1 receptor-dependent pathway in non-small cell lung cancer cell lines. J. Biol. Chem. 2002, 277 (51), 49127-49133
30. Ross, P. L.; Huang, Y. N.; Marchese, J. N.; Williamson, B.; Parker, K.; Hattan, S.; Khainovski, N.; Pillai, S.; Dey, S.; Daniels, S.; Purkayastha, S.; Juhasz, P.; Martin, S.; Bartlet-Jones, M.; He, F.; Jacobson, A.; Pappin, D. J. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics 2004, 3 (12), 1154-1169
31. Horth, P.; Miller, C. A.; Preckel, T.; Wenz, C. Efficient fractionation and improved protein identification by peptide OFFGEL electrophoresis. Mol. Cell. Proteomics 2006, 5 (10), 1968-1974 (Pubitemid 44688204)
32. Chenau, J.; Michelland, S.; Sidibe, J.; Seve, M. Peptides OFFGEL electrophoresis: a suitable pre-analytical step for complex eukaryotic samples fractionation compatible with quantitative iTRAQ labeling. Proteome Sci 2008, 6, 9.
33. Shilov, I. V.; Seymour, S. L.; Patel, A. A.; Loboda, A.; Tang, W. H.; Keating, S. P.; Hunter, C. L.; Nuwaysir, L. M.; Schaeffer, D. A. The Paragon Algorithm, a next generation search engine that uses sequence temperature values and feature probabilities to identify peptides from tandem mass spectra. Mol. Cell. Proteomics 2007, 6 (9), 1638-1655
34. Peng, J.; Elias, J. E.; Thoreen, C. C.; Licklider, L. J.; Gygi, S. P. Evaluation of multidimensional chromatography coupled with tandem mass spectrometry (LC/LC-MS/MS) for large-scale protein analysis: the yeast proteome. J. Proteome Res. 2003, 2 (1), 43-50.
35. Goldman, D.; Merril, C. R.; Ebert, M. H. Two-dimensional gel electrophoresis of cerebrospinal fluid proteins. Clin. Chem. 1980, 26 (9), 1317-1322 (Pubitemid 10035235)
36. Shevchenko, A.; Wilm, M.; Vorm, O.; Mann, M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 1996, 68 (5), 850-858 (Pubitemid 26101214)
37. Bendtsen, J. D.; Nielsen, H.; von Heijne, G.; Brunak, S. Improved prediction of signal peptides: SignalP 3.0. J. Mol. Biol. 2004, 340 (4), 783-795 (Pubitemid 38829638)
38. Nielsen, H.; Engelbrecht, J.; Brunak, S.; von Heijne, G. Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites. Protein Eng. 1997, 10 (1), 1-6. (Pubitemid 27073346)
39. Bendtsen, J. D.; Jensen, L. J.; Blom, N.; Von Heijne, G.; Brunak, S. Feature-based prediction of non-classical and leaderless protein secretion. Protein Eng. Des. Sel. 2004, 17 (4), 349-356 (Pubitemid 39093515)
40. Gorg, A.; Weiss, W.; Dunn, M. J. Current two-dimensional electrophoresis technology for proteomics. Proteomics 2004, 4 (12), 3665-3685
41. Flatt, P. M.; Polyak, K.; Tang, L. J.; Scatena, C. D.; Westfall, M. D.; Rubinstein, L. A.; Yu, J.; Kinzler, K. W.; Vogelstein, B.; Hill, D. E.; Pietenpol, J. A. p53-dependent expression of PIG3 during proliferation, genotoxic stress, and reversible growth arrest. Cancer Lett. 2000, 156 (1), 63-72. (Pubitemid 30326769)
42. Contente, A.; Dittmer, A.; Koch, M. C.; Roth, J.; Dobbelstein, M. A polymorphic microsatellite that mediates induction of PIG3 by p53. Nat. Genet. 2002, 30 (3), 315-320 (Pubitemid 34887692)
43. Wong, J.; Li, P. X.; Klamut, H. J. A novel p53 transcriptional repressor element (p53TRE) and the asymmetrical contribution of two p53 binding sites modulate the response of the placental transforming growth factor-beta promoter to p53. J. Biol. Chem. 2002, 277 (29), 26699-26707
44. Yang, H.; Filipovic, Z.; Brown, D.; Breit, S. N.; Vassilev, L. T. Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation. Mol. Cancer Ther. 2003, 2 (10), 1023-1029
45. Buckbinder, L.; Talbott, R.; Velasco-Miguel, S.; Takenaka, I.; Faha, B.; Seizinger, B. R.; Kley, N. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995, 377 (6550), 646-649
46. Grimberg, A.; Liu, B.; Bannerman, P.; El-Deiry, W. S.; Cohen, P. IGFBP-3 mediates p53-induced apoptosis during serum starvation. Int. J. Oncol. 2002, 21 (2), 327-335
47. Spiesbach, K.; Tannapfel, A.; Mossner, J.; Engeland, K. TAp63gamma can substitute for p53 in inducing expression of the maspin tumor suppressor. Int. J. Cancer 2005, 114 (4), 555-562 (Pubitemid 40349613)
48. Ito, R.; Nakayama, H.; Yoshida, K.; Oda, N.; Yasui, W. Loss of maspin expression is associated with development and progression of gastric carcinoma with p53 abnormality. Oncol. Rep. 2004, 12 (5), 985-990
49. Kunz, C.; Pebler, S.; Otte, J.; von der Ahe, D. Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. Nucleic Acids Res. 1995, 23 (18), 3710-3717
50. Shetty, S.; Gyetko, M. R.; Mazar, A. P. Induction of p53 by urokinase in lung epithelial cells. J. Biol. Chem. 2005, 280 (30), 28133-28141
51. Lee, J. S.; Kim, H. S.; Park, J. T.; Lee, M. C.; Park, C. S. Expression of vascular endothelial growth factor in the progression of cervical neoplasia and its relation to angiogenesis and p53 status. Anal. Quant. Cytol. Histol. 2003, 25 (6), 303-311 (Pubitemid 38044607)
52. Tataria, M.; Quarto, N.; Longaker, M. T.; Sylvester, K. G. Absence of the p53 tumor suppressor gene promotes osteogenesis in mesenchymal stem cells J. Pediatr. Surg. 2006, 41 (4), 624-32, discussion 624-632
53. Kamemura, K.; Hart, G. W. Dynamic interplay between O-glycosylation and O-phosphorylation of nucleocytoplasmic proteins: a new paradigm for metabolic control of signal transduction and transcription. Prog. Nucleic Acid Res. Mol. Biol. 2003, 73, 107-136
54. Pisitkun, T.; Shen, R. F.; Knepper, M. A. Identification and proteomic profiling of exosomes in human urine. Proc. Natl. Acad. Sci. U.S.A. 2004, 101 (36), 13368-13373
55. Yu, X.; Harris, S. L.; Levine, A. J. The regulation of exosome secretion: a novel function of the p53 protein. Cancer Res. 2006, 66 (9), 4795-4801
56. Jin, S.; Levine, A. J. The p53 functional circuit. J. Cell Sci. 2001, 114 (Pt 23), 4139-4140
57. Rao, J. S. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat. Rev. Cancer 2003, 3 (7), 489-501.
58. Borgono, C. A.; Diamandis, E. P. The emerging roles of human tissue kallikreins in cancer. Nat. Rev. Cancer 2004, 4 (11), 876-890 (Pubitemid 39472954)
59. Guarino, M.; Rubino, B.; Ballabio, G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology 2007, 39 (3), 305-318 (Pubitemid 46897605)
60. Xie, M. H.; Holcomb, I.; Deuel, B.; Dowd, P.; Huang, A.; Vagts, A.; Foster, J.; Liang, J.; Brush, J.; Gu, Q.; Hillan, K.; Goddard, A.; Gurney, A. L. FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 1999, 11 (10), 729-735 (Pubitemid 29460470)
61. Abuharbeid, S.; Czubayko, F.; Aigner, A. The fibroblast growth factor-binding protein FGF-BP. Int. J. Biochem. Cell Biol. 2006, 38 (9), 1463-1468 (Pubitemid 43729304)
62. Liaudet-Coopman, E. D.; Berchem, G. J.; Wellstein, A. In vivo inhibition of angiogenesis and induction of apoptosis by retinoic acid in squamous cell carcinoma. Clin. Cancer Res. 1997, 3 (2), 179-184 (Pubitemid 27107292)
63. Czubayko, F.; Liaudet-Coopman, E. D.; Aigner, A.; Tuveson, A. T.; Berchem, G. J.; Wellstein, A. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat. Med. 1997, 3 (10), 1137-1140 (Pubitemid 27444457)
64. Kagara, N.; Tanaka, N.; Noguchi, S.; Hirano, T. Zinc and its transporter ZIP10 are involved in invasive behavior of breast cancer cells. Cancer Sci. 2007, 98 (5), 692-697
65. Ruiz de Almodovar, C.; Ruiz-Ruiz, C.; Rodriguez, A.; Ortiz-Ferron, G.; Redondo, J. M.; Lopez-Rivas, A. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) decoy receptor TRAIL-R3 is upregulated by p53 in breast tumor cells through a mechanism involving an intronic p53-binding site. J. Biol. Chem. 2004, 279(6), 4093-4101 (Pubitemid 38198993)
66. Todorovicc, V.; Chen, C. C.; Hay, N.; Lau, L. F. The matrix protein CCN1 (CYR61) induces apoptosis in fibroblasts. J. Cell Biol. 2005, 171 (3), 559-568
67. Yoon, H.; Liyanarachchi, S.; Wright, F. A.; Davuluri, R.; Lockman, J. C.; de la Chapelle, A.; Pellegata, N. S. Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53. Proc. Natl. Acad. Sci. U.S.A. 2002, 99 (24), 15632-15637
68. Collavin, L.; Lazarevic, D.; Utrera, R.; Marzinotto, S.; Monte, M.; Schneider, C. wt p53 dependent expression of a membrane-associated isoform of adenylate kinase. Oncogene 1999, 18 (43), 5879-5888
69. Ito, S.; Fukusato, T.; Nemoto, T.; Sekihara, H.; Seyama, Y.; Kubota, S. Coexpression of glucose transporter 1 and matrix metalloproteinase-2 in human cancers. J. Natl. Cancer Inst. 2002, 94 (14), 1080-1091 (Pubitemid 34830728)
70. Jin, Y. J.; Wang, J.; Qiao, C.; Hei, T. K.; Brandt-Rauf, P. W.; Yin, Y. A novel mechanism for p53 to regulate its target gene ECK in signaling apoptosis. Mol. Cancer Res. 2006, 4 (10), 769-778 (Pubitemid 44683316)
71. Levina, E.; Oren, M.; Ben-Ze'ev, A. Downregulation of beta-catenin by p53 involves changes in the rate of beta-catenin phosphorylation and Axin dynamics. Oncogene 2004, 23 (25), 4444-4453
72. Hara, S.; Nakashima, S.; Kiyono, T.; Sawada, M.; Yoshimura, S.; Iwama, T.; Banno, Y.; Shinoda, J.; Sakai, N. p53-Independent ceramide formation in human glioma cells during gamma-radiation-induced apoptosis. Cell Death Differ. 2004, 11 (8), 853-861
73. Atencio, I. A.; Ramachandra, M.; Shabram, P.; Demers, G. W. Calpain inhibitor 1 activates p53-dependent apoptosis in tumor cell lines. Cell Growth Differ. 2000, 11 (5), 247-253 (Pubitemid 30347204)
74. Thomas, A.; Giesler, T.; White, E. p53 mediates bcl-2 phosphorylation and apoptosis via activation of the Cdc42/JNK1 pathway. Oncogene 2000, 19 (46), 5259-5269
75. Gadea, G.; Lapasset, L.; Gauthier-Rouviere, C.; Roux, P. Regulation of Cdc42-mediated morphological effects: a novel function for p53. EMBO J. 2002, 21 (10), 2373-2382 (Pubitemid 34546710)
76. Okuyama, T.; Kurata, S.; Tomimori, Y.; Fukunishi, N.; Sato, S.; Osada, M.; Tsukinoki, K.; Jin, H. F.; Yamashita, A.; Ito, M.; Kobayashi, S.; Hata, R. I.; Ikawa, Y.; Katoh, I. p63(TP63) elicits strong trans-activation of the MFG-E8/lactadherin/BA46 gene through interactions between the TA and DeltaN isoforms. Oncogene 2008, 27 (3), 308-317
77. Orre, L. M.; Pernemalm, M.; Lengqvist, J.; Lewensohn, R.; Lehtio, J. Up-regulation, modification, and translocation of S100A6 induced by exposure to ionizing radiation revealed by proteomics profiling. Mol. Cell. Proteomics 2007, 6 (12), 2122-2131
78. Oshiro, M. M.; Futscher, B. W.; Lisberg, A.; Wozniak, R. J.; Klimecki, W. T.; Domann, F. E.; Cress, A. E. Epigenetic regulation of the cell type-specific gene 14-3-3sigma. Neoplasia 2005, 7 (9), 799-808.
79. Gu, Y. M.; Jin, Y. H.; Choi, J. K.; Baek, K. H.; Yeo, C. Y.; Lee, K. Y. Protein kinase A phosphorylates and regulates dimerization of 14-3-3 epsilon. FEBS Lett. 2006, 580 (1), 305-310
80. Dohn, M.; Jiang, J.; Chen, X. Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis. Oncogene 2001, 20 (45), 6503-6515 (Pubitemid 32980275)
81. Criswell, T.; Klokov, D.; Beman, M.; Lavik, J. P.; Boothman, D. A. Repression of IR-inducible clusterin expression by the p53 tumor suppressor protein. Cancer Biol. Ther. 2003, 2 (4), 372-380
82. Pugacheva, E. N.; Ivanov, A. V.; Kravchenko, J. E.; Kopnin, B. P.; Levine, A. J.; Chumakov, P. M. Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil. Oncogene 2002, 21 (30), 4595-4600
83. Rother, K.; Dengl, M.; Lorenz, J.; Tschop, K.; Kirschner, R.; Mossner, J.; Engeland, K. Gene expression of cyclin-dependent kinase subunit Cks2 is repressed by the tumor suppressor p53 but not by the related proteins p63 or p73. FEBS Lett. 2007, 581 (6), 1166-1172 (Pubitemid 46385940)
84. Yun, J.; Chae, H. D.; Choy, H. E.; Chung, J.; Yoo, H. S.; Han, M. H.; Shin, D. Y. p53 negatively regulates cdc2 transcription via the CCAAT-binding NF-Y transcription factor. J. Biol. Chem. 1999, 274 (42), 29677-29682 (Pubitemid 29483335)
85. Harada, H.; Nakagawa, K.; Saito, M.; Kohno, S.; Nagato, S.; Furukawa, K.; Kumon, Y.; Hamada, K.; Ohnishi, T. Introduction of wild-type p53 enhances thrombospondin-1 expression in human glioma cells. Cancer Lett. 2003, 191 (1), 109-119 (Pubitemid 36254783)
86. Peterson, E. J.; Bogler, O.; Taylor, S. M. p53-mediated repression of DNA methyltransferase 1 expression by specific DNA binding. Cancer Res. 2003, 63 (20), 6579-6582 (Pubitemid 37322935)
87. Zhang, L.; Zhan, Q.; Zhan, S.; Kashanchi, F.; Fornace, A. J., Jr.; Seth, P.; Helman, L. J. p53 regulates human insulin-like growth factor II gene expression through active P4 promoter in rhabdomyosarcoma cells. DNA Cell Biol. 1998, 17 (2), 125-131 (Pubitemid 28113861)
88. Guida, T.; Salvatore, G.; Faviana, P.; Giannini, R.; Garcia-Rostan, G.; Provitera, L.; Basolo, F.; Fusco, A.; Carlomagno, F.; Santoro, M. Mitogenic effects of the up-regulation of minichromosome maintenance proteins in anaplastic thyroid carcinoma. J. Clin. Endocrinol. Metab. 2005, 90 (8), 4703-4709 (Pubitemid 41159361)
89. Grimberg, A.; Coleman, C. M.; Shi, Z.; Burns, T. F.; MacLachlan, T. K.; Wang, W.; El-Deiry, W. S. Insulin-like growth factor factor binding protein-2 is a novel mediator of p53 inhibition of insulin-like growth factor signaling. Cancer Biol. Ther. 2006, 5 (10), 1408-1414
90. Sembritzki, O.; Hagel, C.; Lamszus, K.; Deppert, W.; Bohn, W. Cytoplasmic localization of wild-type p53 in glioblastomas correlates with expression of vimentin and glial fibrillary acidic protein. Neuro-Oncology 2002, 4 (3), 171-178 (Pubitemid 35214753)
91. Shou, J.; Ali-Osman, F.; Multani, A. S.; Pathak, S.; Fedi, P.; Srivenugopal, K. S. Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA. Oncogene 2002, 21 (6), 878-889
92. Hidaka, H.; Ishiko, T.; Ishikawa, S.; Ikeda, O.; Mita, S.; Iwamura, T.; Chijiiwa, K.; Ogawa, M. Constitutive IL-8 expression in cancer cells is associated with mutation of p53. J. Exp. Clin. Cancer Res. 2005, 24 (1), 127-133 (Pubitemid 40655873)
93. Jonson, T.; Albrechtsson, E.; Axelson, J.; Heidenblad, M.; Gorunova, L.; Johansson, B.; Hoglund, M. Altered expression of TGFB receptors and mitogenic effects of TGFB in pancreatic carcinomas. Int. J. Oncol. 2001, 19 (1), 71-81. (Pubitemid 32121832)